ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2217

Even After Pretreatment with up to Three Biologics, Anti-TNFs Shows Effectiveness in Active Psoriatic Arthritis Patients

Frank Behrens1, Michaela Koehm1, Diamant Thaci2, Brigitte Krummel-Lorenz3, Gerd Greger4, Bianca Wittig4 and Harald Burkhardt5, 1CIRI/Div. Rheumatology, J.W. Goethe-University, Frankfurt/Main, Germany, 2Klinik für Dermatologie, Venerologie und Allergologie, J.W. Goethe University, Frankfurt/Main, Germany, 3CIRI/Endokrinologikum, Frankfurt/Main, Germany, 4Abbott GmbH & Co KG, Wiesbaden, Germany, 5CIRI /Div. of Rheumatology, Goethe-University, Frankfurt/Main, Frankfurt/Main, Germany

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Adalimumab, anti-TNF therapy, disease-modifying antirheumatic drugs and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose: For the treatment of patients with psoriatic arthritis (PsA) only antiTNF biologics are licensed. Therefore, failures to anti-TNF are often switched to a different antiTNF treatment, despite the fact that only little evidence of effectiveness is available for anti TNF switch.

Methods: A multicentre, prospective observational study included patients (n=3320) with moderate to severe PsA treated with Adalimumab (ADA). Treatment response of ADA therapy when used as first-, second- or third/fourth line antiTNF-therapy regimen in patients with active psoriatic arthritis in clinical routine care in Germany was measured. Besides documentation of demographic data, disease activity assessments such as number of swollen (SJC) and tender joints (TJC), disease activity score 28 (DAS28), enthesitis, dactylitis as well as target lesion score (TLS) and body surface area (BSA) for skin involvement were calculated at baseline, month 3, 6, 12 and 24. 

Results: Treatment with ADA is effective in patients with active PsA. The reduction of disease activity is clinical meaningful independently from the number of previous used antiTNF agents (0, 1, ≥ 2). The swollen joint count (SJC) was reduced from 8.7 at baseline to 1.4 after 24 months (TNFnaive). A comparable reduction was seen in patients pretreated with one (7.7 to 2.8) or two and more (8.5 to 1.9) antiTNF agents.

A higher reduction in DAS28 was seen in the group of biologic naive patients (-2.22) than in those with pretreatment of at least one TNF (-1.79). This leads to a mean DAS after two years of treatment with ADA near to remission (DAS28 2.62) while those switching to ADA from another TNF achieved a mean DAS of 2.89 (failed one antiTNF) and 3.12 (failed two or more antiTNF) respectively. Comparable reduction of percentages of patients with dactylitis was seen in all groups while enthesitis responses better in TNF naïve versus those who faile one or more antiTNF. Additionally, skin response in all groups was comparable measured by reduction in TLS. 

Conclusion: ADA treatment is effective in patients with active PsA on all facets of the disease (arthritis, enthesitis, dactylitis and skin involvement). A switch from another antiTNF results in a meaningful reduction of disease activity. In contrast to rheumatoid arthritis in which previous antiTNF use leads to a significant decrease of response, in PsA the reduction in SJC is independent from a pretreatment with antiTNF agents. Nevertheless, the mean DAS after two years of treatment was significant lower in antiTNF naive patients than in those with up to 3 previous biologics.


Disclosure:

F. Behrens,

Abbott Immunology Pharmaceuticals,

5,

Abbott Immunology Pharmaceuticals,

8;

M. Koehm,
None;

D. Thaci,

Abbott Immunology Pharmaceuticals,

5,

Abbott Immunology Pharmaceuticals,

8;

B. Krummel-Lorenz,

Abbott Immunology Pharmaceuticals,

5;

G. Greger,

Abbott Immunology Pharmaceuticals,

3;

B. Wittig,

Abbott Immunology Pharmaceuticals,

3;

H. Burkhardt,

Abbott Immunology Pharmaceuticals,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/even-after-pretreatment-with-up-to-three-biologics-anti-tnfs-shows-effectiveness-in-active-psoriatic-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology